These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 29670620)
1. Semaphorin3A: A Potential Therapeutic Tool for Lupus Nephritis. Bejar J; Kessler O; Sabag AD; Sabo E; Itzhak OB; Neufeld G; Vadasz Z Front Immunol; 2018; 9():634. PubMed ID: 29670620 [TBL] [Abstract][Full Text] [Related]
2. Low Urine Secretion of Semaphorin3A in Lupus Patients with Proteinuria. Doron R; Merav L; Nasrin E; Adi SD; Elias T; Gleb S; Itzhak R; Michael R; Zahava V Inflammation; 2022 Apr; 45(2):603-609. PubMed ID: 34562225 [TBL] [Abstract][Full Text] [Related]
3. Glomerular Proteomic Profiles in the NZB/W F1 Hybrid Mouse Model of Lupus Nephritis. Xue L; Shuyan T; Xiaoli L; Zilong L; Qiuling F; Lining W; Yanqiu L; Li Y Med Sci Monit; 2019 Mar; 25():2122-2131. PubMed ID: 30900683 [TBL] [Abstract][Full Text] [Related]
4. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32). Werwitzke S; Trick D; Sondermann P; Kamino K; Schlegelberger B; Kniesch K; Tiede A; Jacob U; Schmidt RE; Witte T Ann Rheum Dis; 2008 Feb; 67(2):154-61. PubMed ID: 17557887 [TBL] [Abstract][Full Text] [Related]
5. Bortezomib treatment prevents glomerulosclerosis associated with lupus nephritis in a murine model through suppressive effects on the immune and renin-angiotensin systems. Matsuki-Muramoto Y; Nozawa K; Uomori K; Sekigawa I; Takasaki Y Mod Rheumatol; 2017 Jan; 27(1):77-86. PubMed ID: 27166507 [TBL] [Abstract][Full Text] [Related]
6. Bcl-2 as a Therapeutic Target in Human Tubulointerstitial Inflammation. Ko K; Wang J; Perper S; Jiang Y; Yanez D; Kaverina N; Ai J; Liarski VM; Chang A; Peng Y; Lan L; Westmoreland S; Olson L; Giger ML; Chun Wang L; Clark MR Arthritis Rheumatol; 2016 Nov; 68(11):2740-2751. PubMed ID: 27159593 [TBL] [Abstract][Full Text] [Related]
7. Curcumin attenuates lupus nephritis upon interaction with regulatory T cells in New Zealand Black/White mice. Lee H; Kim H; Lee G; Chung HS; Bae H Br J Nutr; 2013 Jul; 110(1):69-76. PubMed ID: 23181951 [TBL] [Abstract][Full Text] [Related]
8. Semaphorin 3A - a marker for disease activity and a potential putative disease-modifying treatment in systemic lupus erythematosus. Vadasz Z; Toubi E Lupus; 2012 Oct; 21(12):1266-70. PubMed ID: 22875653 [TBL] [Abstract][Full Text] [Related]
9. Soluble receptor for advanced glycation end products alleviates nephritis in (NZB/NZW)F1 mice. Lee SW; Park KH; Park S; Kim JH; Hong SY; Lee SK; Choi D; Park YB Arthritis Rheum; 2013 Jul; 65(7):1902-12. PubMed ID: 23553192 [TBL] [Abstract][Full Text] [Related]
10. The beneficial effects of treatment with all-trans-retinoic acid plus corticosteroid on autoimmune nephritis in NZB/WF mice. Nozaki Y; Yamagata T; Yoo BS; Sugiyama M; Ikoma S; Kinoshita K; Funauchi M; Kanamaru A Clin Exp Immunol; 2005 Jan; 139(1):74-83. PubMed ID: 15606616 [TBL] [Abstract][Full Text] [Related]
11. Lack of effect of a single injection of human C-reactive protein on murine lupus or nephrotoxic nephritis. Carlucci F; Cook HT; Garg A; Pepys MB; Botto M Arthritis Rheum; 2010 Jan; 62(1):245-9. PubMed ID: 20039408 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of lupus disease by anti-double-stranded DNA antibodies of the IgM isotype in the (NZB x NZW)F1 mouse. Werwitzke S; Trick D; Kamino K; Matthias T; Kniesch K; Schlegelberger B; Schmidt RE; Witte T Arthritis Rheum; 2005 Nov; 52(11):3629-38. PubMed ID: 16255055 [TBL] [Abstract][Full Text] [Related]
13. Tuftsin-phosphorylcholine (TPC) equally effective to methylprednisolone in ameliorating lupus nephritis in a mice model. Shemer A; Kivity S; Shovman O; Bashi T; Perry O; Watad A; Ben-Ami Shor D; Volkov A; Barshack I; Bragazzi NL; Krule A; Fridkin M; Amital H; Blank M; Shoenfeld Y Clin Exp Immunol; 2018 Aug; 193(2):160-166. PubMed ID: 29698559 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of the alternative complement pathway by antisense oligonucleotides targeting complement factor B improves lupus nephritis in mice. Grossman TR; Hettrick LA; Johnson RB; Hung G; Peralta R; Watt A; Henry SP; Adamson P; Monia BP; McCaleb ML Immunobiology; 2016 Jun; 221(6):701-8. PubMed ID: 26307001 [TBL] [Abstract][Full Text] [Related]
15. Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition. Schiffer L; Sinha J; Wang X; Huang W; von Gersdorff G; Schiffer M; Madaio MP; Davidson A J Immunol; 2003 Jul; 171(1):489-97. PubMed ID: 12817034 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic impact of the ethyl acetate extract of Tripterygium wilfordii Hook F on nephritis in NZB/W F1 mice. Tao X; Fan F; Hoffmann V; Longo NS; Lipsky PE Arthritis Res Ther; 2006; 8(1):R24. PubMed ID: 16507125 [TBL] [Abstract][Full Text] [Related]
17. HSPB5 suppresses renal inflammation and protects lupus-prone NZB/W F1 mice from severe renal damage. Knapp J; Braunstein M; Berg SIT; Shirriff C Arthritis Res Ther; 2022 Dec; 24(1):267. PubMed ID: 36510250 [TBL] [Abstract][Full Text] [Related]
18. Somatostatin treatment attenuates proteinuria and prevents weight loss in NZB/W F1 mice. Paran D; Bernheim J; Golan I; Caspi D; Bernheim J; Benchetrit S Lupus; 2006; 15(8):526-31. PubMed ID: 16942006 [TBL] [Abstract][Full Text] [Related]
19. Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. Zoja C; Benigni A; Noris M; Corna D; Casiraghi F; Pagnoncelli M; Rottoli D; Abbate M; Remuzzi G Kidney Int; 2001 Aug; 60(2):653-63. PubMed ID: 11473648 [TBL] [Abstract][Full Text] [Related]
20. The Ox40/Ox40 Ligand Pathway Promotes Pathogenic Th Cell Responses, Plasmablast Accumulation, and Lupus Nephritis in NZB/W F1 Mice. Sitrin J; Suto E; Wuster A; Eastham-Anderson J; Kim JM; Austin CD; Lee WP; Behrens TW J Immunol; 2017 Aug; 199(4):1238-1249. PubMed ID: 28696253 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]